Affiliated Laboratory, INC.

Affiliated Laboratory, INC. was paid $6.51M by Medicaid between Jan 2018 and Mar 2024, across 188 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 9.6% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Maine

Rank by total paid#2 of 10

Median peer was paid$404K

This provider vs. median16×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	125,012	$732K
2019	138,619	$941K
2020	140,533	$1.11M
2021	166,568	$1.59M
2022	186,034	$1.71M
2023	55,889	$414K
2024incomplete	980	$12K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	9.6%	11,096	9,888	$622K
84443	Thyroid stimulating hormone (TSH)	8.0%	51,902	48,168	$519K
80053	Comprehensive metabolic panel	7.0%	79,253	70,947	$453K
80061	Lipid panel	5.6%	48,812	45,426	$367K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	5.2%	19,856	18,374	$337K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	4.5%	72,492	62,572	$295K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	3.1%	6,628	5,591	$200K
87631		2.9%	3,183	2,949	$190K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	2.8%	3,395	2,595	$182K
83036	Hemoglobin; glycosylated (A1C)	2.7%	33,186	30,954	$175K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	2.3%	6,871	6,378	$152K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	2.3%	6,867	6,374	$151K

176 more codes

U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.9%	8,834	$125K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	1.4%	4,580	$93K
82728		1.4%	12,627	$92K
87522	Neg quan hep c or qual rna	1.4%	2,704	$90K
36415	Collection of venous blood by venipuncture	1.4%	82,025	$90K
82607		1.3%	11,765	$87K
80074		1.3%	2,432	$83K
86803		1.2%	8,450	$78K
87086	Culture, bacterial; quantitative colony count, urine	1.2%	16,407	$77K
87390		1.2%	4,924	$76K
87902		1.1%	1,003	$70K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	2,370	$63K
84439		<1%	11,502	$62K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	1,195	$58K
84403		<1%	3,082	$56K
83970		<1%	3,715	$55K
80048	Basic metabolic panel (calcium, ionized)	<1%	18,450	$52K
83550		<1%	11,397	$49K
86702		<1%	4,931	$46K
85027		<1%	13,926	$42K
83540		<1%	12,260	$41K
82746		<1%	5,518	$41K
86701		<1%	4,929	$38K
84702		<1%	2,864	$37K
86140		<1%	10,799	$35K
87070		<1%	5,166	$35K
86706		<1%	4,317	$35K
84153		<1%	3,546	$34K
86618		<1%	3,111	$34K
84146		<1%	2,402	$33K
83880		<1%	2,684	$33K
87340		<1%	3,973	$31K
83735		<1%	10,518	$31K
86038		<1%	3,663	$31K
86704		<1%	3,276	$30K
87081		<1%	5,894	$30K
87077		<1%	8,205	$29K
80055		<1%	739	$28K
80164		<1%	3,737	$25K
83001		<1%	1,582	$23K
87186		<1%	5,000	$22K
84481		<1%	2,042	$22K
82670		<1%	949	$21K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	378	$20K
83516		<1%	1,771	$20K
86665		<1%	771	$19K
87205		<1%	6,041	$19K
84270		<1%	1,230	$19K
80178		<1%	4,194	$18K
82043		<1%	7,708	$18K
85610		<1%	10,432	$17K
84480		<1%	1,735	$17K
83002		<1%	1,074	$16K
80076		<1%	2,926	$15K
82784		<1%	2,111	$15K
85652		<1%	9,010	$15K
86003		<1%	262	$15K
86376		<1%	1,268	$14K
84600		<1%	1,182	$14K
86431		<1%	3,104	$12K
86708		<1%	1,240	$12K
86592		<1%	3,620	$12K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	323	$11K
83690		<1%	2,409	$11K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	629	$11K
87328		<1%	1,148	$9K
87329		<1%	1,140	$9K
86664		<1%	723	$9K
83525		<1%	937	$9K
84402		<1%	489	$9K
80050	General health panel	<1%	481	$9K
83721		<1%	1,605	$8K
86696		<1%	510	$8K
86800		<1%	711	$8K
82150		<1%	1,791	$8K
82140		<1%	1,160	$8K
82977		<1%	1,474	$8K
81001		<1%	5,525	$7K
86762		<1%	647	$7K
87427		<1%	936	$7K
86787		<1%	689	$7K
82570		<1%	2,647	$7K
87046		<1%	991	$7K
82533		<1%	592	$7K
84425		<1%	472	$6K
87045		<1%	1,009	$6K
82248		<1%	1,929	$6K
83993		<1%	402	$6K
84165		<1%	1,314	$6K
80069		<1%	1,752	$6K
84550		<1%	3,170	$6K
86200		<1%	640	$5K
86695		<1%	510	$5K
84100		<1%	2,996	$5K
85046		<1%	1,788	$5K
86481		<1%	121	$5K
82550		<1%	1,374	$5K
85379		<1%	764	$5K
87338		<1%	542	$5K
87075		<1%	784	$5K
83921		<1%	524	$5K
86765		<1%	437	$4K
86364		<1%	674	$4K
82105		<1%	360	$4K
80156		<1%	686	$4K
80175		<1%	601	$4K
87493		<1%	319	$4K
85730		<1%	746	$4K
84156		<1%	2,318	$4K
82950		<1%	892	$4K
86735		<1%	347	$4K
86160		<1%	240	$3K
80177		<1%	615	$3K
86617		<1%	156	$3K
84460		<1%	960	$3K
81003		<1%	2,426	$3K
86235		<1%	81	$3K
84450		<1%	858	$3K
83615		<1%	795	$3K
86225		<1%	279	$3K
83520		<1%	250	$3K
80159		<1%	456	$3K
82652		<1%	95	$2K
82565		<1%	1,121	$2K
86141		<1%	292	$2K
81015		<1%	1,347	$2K
86039		<1%	259	$2K
82310		<1%	810	$2K
82947		<1%	820	$2K
82274		<1%	307	$2K
85018		<1%	1,566	$2K
84466		<1%	276	$2K
82785		<1%	155	$2K
84703		<1%	264	$2K
83883		<1%	169	$2K
84484		<1%	247	$2K
84520		<1%	585	$2K
85014		<1%	1,217	$2K
84132		<1%	818	$1K
82247		<1%	265	$1K
83655		<1%	79	$904.50
86308		<1%	199	$895.27
86694		<1%	80	$811.60
86663		<1%	72	$708.48
86769		<1%	27	$628.31
82627		<1%	28	$511.43
84436		<1%	127	$510.99
86255		<1%	40	$500.17
86901		<1%	331	$473.51
80185		<1%	103	$417.31
86666		<1%	14	$401.24
G0472	Hepatitis c antibody screening, for individual at high risk and other covered indication(s)	<1%	754	$363.12
86900		<1%	285	$362.25
86850		<1%	112	$343.74
86677		<1%	25	$331.33
87252		<1%	16	$325.83
82677		<1%	16	$318.32
84207		<1%	12	$305.47
84134		<1%	44	$281.31
87254		<1%	16	$265.24
83498		<1%	12	$246.74
86336		<1%	16	$214.74
84163		<1%	16	$210.70
84305		<1%	12	$190.08
83090		<1%	13	$163.33
82103		<1%	14	$151.53
84681		<1%	13	$151.38
86256		<1%	14	$144.60
G0433	Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening	<1%	293	$134.96
86015		<1%	12	$88.77
84166		<1%	17	$83.39
89055		<1%	15	$47.89
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	890	$18.85
G0328	Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous	0%	13	$0.00
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	0%	41	$0.00
U0001	Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel	0%	16	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialPOMEROY, KAREN (VICE PRESIDENT)